Replimune Group (NASDAQ:REPL) Trading 3.8% Higher After Analyst Upgrade

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s share price rose 3.8% during trading on Wednesday after JPMorgan Chase & Co. raised their price target on the stock from $14.00 to $17.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Replimune Group traded as high as $11.50 and last traded at $11.49. Approximately 89,276 shares were traded during trading, a decline of 92% from the average daily volume of 1,124,411 shares. The stock had previously closed at $11.07.

Several other equities analysts have also issued reports on REPL. Wedbush reiterated an "outperform" rating and issued a $16.00 price target on shares of Replimune Group in a research note on Thursday, June 6th. Roth Capital upgraded Replimune Group to a "strong-buy" rating in a research note on Tuesday, August 27th. Roth Mkm began coverage on Replimune Group in a research note on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price target on the stock. Barclays lifted their price target on Replimune Group from $13.00 to $17.00 and gave the company an "overweight" rating in a research note on Friday, June 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $17.00 price target on shares of Replimune Group in a research note on Monday, September 16th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Replimune Group has an average rating of "Buy" and a consensus price target of $16.80.

Insiders Place Their Bets

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of Replimune Group stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the transaction, the chief financial officer now directly owns 101,057 shares of the company's stock, valued at approximately $1,028,760.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 20.60% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC bought a new stake in Replimune Group in the 1st quarter valued at about $927,000. Jacobs Levy Equity Management Inc. bought a new stake in Replimune Group in the 1st quarter valued at about $1,088,000. Rafferty Asset Management LLC increased its position in Replimune Group by 148.1% in the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company's stock valued at $3,906,000 after buying an additional 276,596 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company's stock worth $53,505,000 after purchasing an additional 699,679 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in Replimune Group during the 4th quarter worth approximately $76,000. 92.53% of the stock is owned by institutional investors.

Replimune Group Price Performance

The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. The business has a fifty day simple moving average of $10.28 and a 200 day simple moving average of $8.46. The stock has a market capitalization of $756.30 million, a P/E ratio of -3.56 and a beta of 1.22.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($0.88) by $0.10. On average, analysts expect that Replimune Group, Inc. will post -3.11 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.